CalciMedica (CALC) Competitors $1.61 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.03 (+2.11%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. ORMP, SAVA, JMAC, CLLS, IVVD, ADAG, ENTX, ZNTL, OKYO, and JSPRShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Oramed Pharmaceuticals (ORMP), Cassava Sciences (SAVA), Maxpro Capital Acquisition (JMAC), Cellectis (CLLS), Invivyd (IVVD), Adagene (ADAG), Entera Bio (ENTX), Zentalis Pharmaceuticals (ZNTL), OKYO Pharma (OKYO), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors Oramed Pharmaceuticals Cassava Sciences Maxpro Capital Acquisition Cellectis Invivyd Adagene Entera Bio Zentalis Pharmaceuticals OKYO Pharma Jasper Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment. Does the media refer more to ORMP or CALC? In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than CalciMedica. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 1 mentions for CalciMedica. CalciMedica's average media sentiment score of 1.00 beat Oramed Pharmaceuticals' score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media. Company Overall Sentiment Oramed Pharmaceuticals Neutral CalciMedica Positive Which has more risk and volatility, ORMP or CALC? Oramed Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Do analysts recommend ORMP or CALC? CalciMedica has a consensus price target of $18.00, suggesting a potential upside of 1,018.01%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CalciMedica 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, ORMP or CALC? CalciMedica has lower revenue, but higher earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M65.85-$19.06M-$0.44-4.91CalciMedicaN/AN/A-$13.70M-$1.56-1.03 Is ORMP or CALC more profitable? Oramed Pharmaceuticals' return on equity of -11.34% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -11.34% -10.73% CalciMedica N/A -171.81%-100.43% Do institutionals and insiders have more ownership in ORMP or CALC? 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryOramed Pharmaceuticals and CalciMedica tied by winning 7 of the 14 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.50M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-1.0320.3027.1920.03Price / SalesN/A251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book1.507.397.925.55Net Income-$13.70M-$55.04M$3.17B$248.49M7 Day Performance0.63%3.01%2.18%5.37%1 Month Performance-7.47%-0.21%1.25%6.63%1 Year Performance-62.03%4.48%33.90%21.20% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica3.2903 of 5 stars$1.61flat$18.00+1,018.0%-61.8%$22.50MN/A-1.0330Gap UpORMPOramed Pharmaceuticals0.2575 of 5 stars$2.19-2.9%N/A-14.7%$89.26M$2M-4.9710SAVACassava Sciences3.8766 of 5 stars$1.84+1.4%$54.50+2,870.0%-80.3%$88.17MN/A-1.2230JMACMaxpro Capital AcquisitionN/A$6.56+0.7%N/A+3,111.3%$88.06MN/A0.002,021Gap DownCLLSCellectis3.013 of 5 stars$1.55+1.3%$4.00+158.9%-22.3%$87.82M$49.22M-1.84290IVVDInvivyd3.4235 of 5 stars$0.74+3.4%$5.85+691.6%-34.5%$87.69M$25.38M-0.61100ADAGAdagene1.9725 of 5 stars$1.86-4.6%$8.00+330.1%-33.4%$87.63M$100K0.00260Gap UpHigh Trading VolumeENTXEntera Bio2.0154 of 5 stars$1.91+0.5%$10.00+423.6%+16.8%$86.81M$180K-7.3520News CoveragePositive NewsGap UpZNTLZentalis Pharmaceuticals1.5247 of 5 stars$1.20+3.0%$8.37+600.1%-65.5%$85.98M$67.43M-0.38160OKYOOKYO Pharma1.8292 of 5 stars$2.53-1.6%$7.00+176.7%+141.7%$85.62MN/A0.007Positive NewsJSPRJasper Therapeutics3.3951 of 5 stars$5.72+3.1%$59.25+935.8%-66.7%$85.61MN/A-1.0920News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies Oramed Pharmaceuticals Alternatives Cassava Sciences Alternatives Maxpro Capital Acquisition Alternatives Cellectis Alternatives Invivyd Alternatives Adagene Alternatives Entera Bio Alternatives Zentalis Pharmaceuticals Alternatives OKYO Pharma Alternatives Jasper Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
